medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 4

<< Back Next >>

Ann Hepatol 2015; 14 (4)

Influence of ApoE and FABP2 polymorphisms and environmental factors in the susceptibility to gallstone disease

Martinez-Lopez E, Curiel-Lopez F, Hernandez-Nazara A, Moreno-Luna LE, Ramos-Marquez ME, Roman S, Panduro A

Language: English
References: 48
Page: 515-523
PDF size: 156.55 Kb.


ABSTRACT

Background. Gallstone disease (GSD) is a common chronic disease in the Western hemisphere, yet environmental and genetic factors may be responsible for the variations in the prevalence of GSD among populations. Aim. To analyze the relationship of the ApoE and FABP2 polymorphisms with diet, physical activity and emotional health in patients with GSD from West Mexico. Material and methods. A total of 120 patients with GSD and 370 healthy subjects were enrolled. Anthropometric, biochemical, nutritional, clinical and physical activity parameters were measured. ApoE and FABP2 genotypes were assesed by PCR-RFLPs assays. Results: ApoE E3/E4 genotype and the ApoE E4 allele was highly prevalent among the GSD patients compared to the controls (32% vs. 12.0% and 22% vs. 8.4% respectively p ‹ 0.01). Patients with the Apo E4 allele showed an upward trend of cholesterol levels compared to non-Apo E4 allele carriers (E4 186 ± 30 mg/dL; E3 143 ± 37 mg/dL; E2 129 ± 34 mg/dL). High triglyceride levels were associated with patients that were FABP2 Thr54 allele carriers (p ‹ 0.05) but lacked association with GSD. This may be due to changes in dietary fats after GSD diagnosis, masking the clinical course of the disease. Sedentary lifestyle and negative emotions were detected in 83% and 63% of patients, respectively. Conclusion. These data suggest that the Apo E4 allele could confer genetic susceptibility for the development of GSD among the Mexican population. The Ala54Thr polymorphism of FABP2 was associated with high triglycerides levels, but not to GSD; suggesting that environmental factors modulate such susceptibility.


REFERENCES

  1. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver 2012; 6: 172-87.

  2. Reshetnyak VI. Concept of the pathogenesis and treatment of cholelithiasis. World J Hepatol 2012; 4: 18-34.

  3. Everhart JE. Gallstones and ethnicity in the Americas. J Assoc Acad Minor Phys 2001; 12: 137-43.

  4. Acalovschi M. Cholesterol gallstones: from epidemiology to prevention. Postgrad Med J 2001; 77: 221-29.

  5. Hurt RT, Kulisek C, Buchanan LA, McClave SA. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol 2010; 6: 780-92.

  6. Méndez-Sánchez N, Jessurun J, Ponciano-Rodríguez G, Alonso-de-Ruiz P, Uribe M, Hernández-Avila M. Prevalence of gallstone disease in Mexico. A necropsy study. Dig Dis Sci 1993; 38: 680-3.

  7. Hernández-Nazará A, Curiel-López F, Martínez-López E, Hernández-Nazará Z, Panduro A. Genetic predisposition of cholesterol gallstone disease. Ann Hepatol 2006; 5: 140-9.

  8. Njeze GE. Gallstones. Niger J Surg 2013; 19: 49-55.

  9. Méndez-Sánchez N, Chavez-Tapia NC, Motola-Kuba D, Sanchez-Lara K, Ponciano-Rodríguez G, Baptista H, Ramos MH, et al. Metabolic syndrome as a risk factor for gallstone disease. World J Gastroenterol 2005; 11: 1653-7.

  10. Puppala S, Dodd GD, Fowler S, Arya R, Schneider J, Farook VS, Granato R, et al. A genome wide search finds major susceptibility loci for gallbladder disease on chromosome 1 in Mexican Americans. Am J Hum Genet 2006; 78: 377-92.

  11. Duggirala R, Mitchell BD, Blangero J, Stern MP. Genetic determinants of variation in gallbladder disease in the Mexican- American population. Genet Epidemiol 1999; 16: 191-204.

  12. Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology 2005; 41: 1138-43.

  13. Buch S, Schafmayer C, Völzke H, Becker C, Franke A, von Eller-Eberstein H, Kluck C, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nature Genetics 2007; 39: 995-9.

  14. Lammert F, Sauerbruch T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 423-33.

  15. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1998; 240: 622–30.

  16. Miettinen TA. Impact of apo E phenotype on the regulation of cholesterol metabolism. Ann Med 1991; 23: 181-6.

  17. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982; 257: 2518-21.

  18. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985; 37: 268-85.

  19. Fischer S, Dolu MH, Zünch B, Meyer G, Geister S, Jüngst D. Apolipoprotein E polymorphism and lithogenic factors in gallbladder bile. Eur J Clin Invest 2001; 31: 789-95.

  20. Baier LJ, Sacchettini JC, Knowler WC, Eads J, Paolisso G, Tataranni PA, Mochizuki H, et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding increased fat oxidation and insulin resistance. J Clin Invest 1995; 95: 1281-7.

  21. Baier LJ, Bogardus C, Sacchettini JC. A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells. J Biol Chem 1996; 271: 10892-6.

  22. Georgopoulos A, Aras O, Tsai MY. Codon-54 polymorphism of the fatty acid-binding protein 2 gene is associated with elevation of fasting and postprandial triglyceride in type 2 diabetes. J Clin Endocrinol Metab 2000; 85: 3155-60.

  23. Vidgren HM, Sipiläinen RH, Heikkinen S, Laakso M, Uusitupa MI. Threonine allele in codon 54 of the fatty acid binding protein 2 gene does not modify the fatty acid composition of serum lipids in obese subjects. Eur J Clin Invest 1997; 27: 405-8.

  24. Agren JJ, Vidgren HM, Valve RS, Laakso M, Uusitupa MI. Postprandial responses of individual fatty acids in subjects homozygous for the threonine- or alanine-encoding allele in codon 54 of the intestinal fatty acid binding protein 2 gene. Am Jo Clin Nutr 2001; 73: 31-5.

  25. Yamada K, Yuan X, Ishiyama S, Koyama K, Ichikawa F, Koyanagi A, Koyama W, et al. Association between Ala54Thr substitution of the fatty acid-binding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men. Diabetologia 1997; 40: 706-10.

  26. Juvonen T, Kervinen K, Kairaluoma MI, Lajunen LH, Kesäniemi YA. Gallstone cholesterol content is related to apolipoprotein E polymorphism. Gastroenterology 1993; 104: 1806-13.

  27. Bertomeu A, Ros E, Zambón D, Vela M, Pérez-Ayuso RM, Targarona E, Trías M, et al. Apolipoprotein E polymorphism and gallstones. Gastroenterology 1996; 111: 1603-10.

  28. Mella JG, Schirin-Sokhan R, Rigotti A, Pimentel F, Villarroel L, Wasmuth HE, Sauerbruch T, et al. Genetic evidence that apolipoprotein E4 is not a relevant susceptibility factor for cholelithiasis in two high risk populations. J Lipid Res 2007; 48: 1378-85.

  29. Hasegawa K, Terada S, Kubota K, Itakura H, Imamura H, Ohnishi S, Aoki T, et al. Effect of apolipoprotein E polymorphism on bile lipid composition and the formation of cholesterol gallstone. Am J Gastroenterol 2003; 98: 1605-9.

  30. Sánchez-Cuén J, Aguilar-Medina M, Arámbula-Meraz E, Romero-Navarro J, Granados J, Sicairos-Medina L, Ramos- Payán R, et al. ApoB-100, ApoE and CYP7A1 gene polymorphisms in Mexican patients with cholesterol gallstone disease. World J Gastroenterol 2010; 16: 4685-90.

  31. López-Alvarenga JC, Reyes-Díaz S, Castillo-Martínez L, Dávalos-Ibáñez A, González-Barranco J. Reproducibilidad y sensibilidad de un cuestionario de actividad física en población mexicana. Salud Publica Mex 2001; 43: 306-12.

  32. Ferguson RJ, Robinson AB, Splaine M. Use of the reliable change index to evaluate clinical significance in SF-36 outcomes. Qual Life Res 2002; 11: 509-16.

  33. Vázquez-Vandyck M, Roman S, Vázquez JL, Huacuja L, Khalsa G, Troyo-Sanromán R, Panduro A. Effect of Breathwalk on body composition, metabolic and mood state in chronic hepatitis C patients with insulin resistance syndrome. World J Gastroenterol 2007; 13: 6213-8.

  34. Lukaski HC, Bolonchuk WW, Siders WA, Hall CB. Body composition assessment of athletes using bioelectrical impedance measurements. J Sports Med Phys Fitness 1990; 30: 434-40.

  35. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.

  36. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, et al. European guidelines on cardiovascular disease prevention in clinical practice, Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.

  37. Miller SA, Dikes DD, Polesky HF. A simple salting out procedure for extracting DNA from human cells. Nucleic Acids Res 1988; 16: 1215.

  38. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-8.

  39. Martinez-Lopez E, Garcia-Garcia MR, Gonzalez-Avalos JM, Maldonado-Gonzalez M, Ruiz-Madrigal B, Vizmanos B, Hernandez-Nazara Z, et al. Effect of Ala54Thr polymorphism of FABP2 on anthropometric and biochemical variables in response to a moderate-fat diet. Nutrition 2013; 29: 46-51.

  40. Aceves D, Ruiz B, Nuño P, Roman S, Zepeda E, Panduro A. Heterogeneity of apolipoprotein E polymorphism in different Mexican populations. Hum Biol 2006; 78: 65-75.

  41. Reich D, Patterson N, Campbell D, Tandon A, Mazieres S, Ray N, Parra MV, et al. Reconstructing Native American population history. Nature 2012; 488: 370-4.

  42. Gamboa R, Hernandez-Pacheco G, Hesiquio R, Zuñiga J, Massó F, Montaño LF, Ramos-Kuri M, et al. Apolipoprotein E polymorphism in the Indian and Mestizo populations of Mexico. Hum Biol 2000; 72: 975-81.

  43. Salguero ML, Leon RE, Santos A, Roman S, Segura-Ortega JE, Panduro A. The role of FABP2 gene polymorphism in alcoholic cirrhosis. Hepatol Res 2005; 33: 306-12.

  44. Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gómez Pérez FJ, Rull JA, Rojas R, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res 2001; 42: 1298-307.

  45. Ramos-López O, Roman S, Ojeda-Granados C, Sepúlveda- Villegas M, Martínez-López E, Torres-Valadez R, Trujillo- Trujillo E, et al. Patrón de ingesta alimentaria y actividad física en pacientes hepatópatas en el Occidente de México. Revista de Endocrinología y Nutrición 2013; 21: 7-15 [Spanish].

  46. Kovacs P, Kurtz U, Wittenburg H. Hepatic insulin resistance ties cholesterol gallstone formation and the metabolic syndrome. Annals of Hepatology 2008; 7: 262-4.

  47. Román S, Ojeda-Granados C, Panduro A. Genética y evolución de la alimentación de la población en México. Rev Endocrinol Nutr 2013; 21: 42-51. [Spanish].

  48. Ojeda-Granados C, Panduro A, Ramos-López O, Roman S. Construyendo una dieta correcta con base en el genoma latino. Rev Endocrinol Nutr 2013; 21: 84-92. [Spanish].




2020     |     www.medigraphic.com